PAB 7.14% 0.7¢ patrys limited

patrys granted us patent for lead product pat-

  1. 113 Posts.
    ? Second granted US patent for lead product PAT-LM1 offers protection through to March
    2024
    ? Patent covers the PAT-LM1 antibody and binding fragments

    Melbourne, Australia; 8 November, 2013: Patrys Limited (ASX: PAB), a clinical stage biotechnology
    company is pleased to advise that it has been granted a second US patent for lead anti-cancer
    product PAT-LM1.
 
watchlist Created with Sketch. Add PAB (ASX) to my watchlist
(20min delay)
Last
0.7¢
Change
-0.001(7.14%)
Mkt cap ! $13.37M
Open High Low Value Volume
0.6¢ 0.7¢ 0.6¢ $505 80K

Buyers (Bids)

No. Vol. Price($)
28 5901591 0.6¢
 

Sellers (Offers)

Price($) Vol. No.
0.7¢ 1528945 4
View Market Depth
Last trade - 15.44pm 16/07/2024 (20 minute delay) ?
PAB (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.